At Circular Genomics, we're pioneering a new era in mental health care. By identifying brain-enriched circRNA biomarkers in blood, we're enabling clinicians to predict patient responses to SSRI antidepressants—moving towards personalized, effective treatment planning.

For some patients with #MajorDepressiveDisorder, it can take up to 1 year to find the right treatment. MindLight™ uses circular RNA technology to help predict a patient’s likelihood of response to SSRIs. Learn more: hubs.la/Q03p01vT0

June is Men’s Mental Health Awareness Month — a time to bring attention to the unique mental health challenges men face and to break down the stigma surrounding them. Too often, men are encouraged to stay silent about their struggles. But the truth is: Asking for help is not a

🧠 June is #Alzheimers & #BrainAwareness Month! Take charge of your brain health: ✔️ Move more ✔️ Sleep better ✔️ Eat smart ✔️ Stay mentally active ✔️ Know the signs At Circular Genomics, we're advancing brain health through circular RNA & precision medicine. #GoPurple #ENDALZ

We are excited to share that our CEO, Paul Sargeant, PhD, will be speaking at the Dubai Family Office Investment Summit on June 12, 2025. He’ll be sharing insights on how innovation in Circular RNA is shaping the future of precision medicine in mental health.

We’re thrilled to welcome our Commercial Advisory Board members: Melissa Reilly, JD, MBA; Andrew J. Lechleiter; Laura Viaches; and James Grana, PhD. Their deep expertise across healthcare strategy, growth, and innovation will be invaluable as we advance Circular Genomics’

Justin T. Brown, PhD, our Senior Director of Business Development, will be attending the BIO International Convention June 16–19, 2025 at the Boston Convention & Exhibition Center. Meet with Justin to discuss partnering with us on circRNA-based Dx! #BIO2025

We’re excited to exhibit at the AANP National Conference in San Diego from June 17–22, 2025! Looking forward to connecting with NPs and sharing how genomic innovation is advancing mental health care. Stop by booth 237 to learn more! #AANP2025 #PrecisionPsychiatry #MentalHealth

We are live at the American Association of Nurse Practitioner meeting! Stop by booth #237 to learn how MindLight can improve treatment planning for patients diagnosed with #MajorDepressiveDisorder. #AANP2025 #PrecisionPsychiatry #MentalHealth

Treating Major Depressive Disorder is complex, and the current standard often leaves patients waiting weeks to see if treatment works. For physicians, finding the right antidepressant can feel like educated guesswork. But with the MindLight™ Antidepressant Response Test,

🎙️ Hear Dr. Madhukar Trivedi, Professor of Psychiatry at UT Southwestern Medical School, discuss how the MindLight™ Antidepressant Response Test uses circular RNA to help clinicians make more informed treatment decisions — giving patients the best chance at relief, faster.

Circular Genomics has been awarded a $250K investment from the Alzheimer’s Drug Discovery Foundation to advance our circular RNA blood-based early detection diagnostic testing for Alzheimer’s Disease. Read the full press release here: hubs.la/Q03wdq7H0

Exciting news from our funded investigators Circular Genomics Inc.! Our investment is advancing circRNA, a novel blood-based biomarker for diagnosing and predicting Alzheimer's progression, supported by Diagnostics Accelerators (DxA).

In this week's San Diego Newsletter: Adcentrx gets FDA Orphan Drug nod for gastric cancer drug; Circular Genomics Inc. snags $250K for Alzheimer’s RNA test; Iambic Therapeutics + Revolution Medicine launch partnership; UC San Diego Division of Extended Studies offers Business of Biotech course. Subscribe: bit.ly/4iqn5b1

When it comes to selecting the right treatment for #MDD patients, pharmacogenomic tests (PGx) only tell part of the story — focusing on how the body metabolizes medications. MindLight uses circular RNA to assess a patient's likelihood of response to SSRIs. Learn more:

Finding the right antidepressant for patients with Major Depressive Disorder (MDD) can be complex. The MindLight Antidepressant Response Test™ uses a brain-derived biomarker to help guide treatment decisions by predicting a patient’s likelihood of response and long-term

We’ve launched our newly redesigned website! Explore our circular RNA platform and how our technology is shaping the future of precision Neurology and Psychiatry. Visit na2.hubs.ly/y0Gvg80

Alzheimer’s disease touches us all. It affects not only patients, but also the families and caretakers who walk beside them. At Circular Genomics, we are committed to transforming how neurological and psychiatric conditions are diagnosed and managed—bringing hope to those who

We’re excited to announce that our CEO, Paul Sargeant, PhD, will be presenting at LSI Europe ’25! He will discuss how Circular Genomics is advancing precision medicine in neurology and mental health using brain-enriched circular RNA (circRNA) biomarkers.

Our platform leverages the unique biological properties of circular RNA to enable brain-specific diagnostics and therapeutic discovery. By advancing circRNA innovation, we’re bringing the promise of precision medicine closer to patients living with neurological and psychiatric